A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway.

PharmacoEconomics
Huajie JinSarah Byford

Abstract

Schizophrenia is associated with a high economic burden. Economic models can help to inform resource allocation decisions to maximise benefits to patients. This systematic review aims to assess the availability, quality and consistency of conclusions of health economic models evaluating the cost effectiveness of interventions for schizophrenia. An electronic search was performed on multiple databases (MEDLINE, EMBASE, PsycINFO, Cochrane database of systematic reviews, NHS Economic Evaluation Database and Health Technology Assessment database) to identify economic models of interventions for schizophrenia published between 2005 and 2020. Two independent reviewers selected studies for inclusion. Study quality was assessed using the National Institute for Health and Care Excellence (NICE) checklist and the Cooper hierarchy. Model characteristics and conclusions were descriptively summarised. Seventy-three models met inclusion criteria. Seventy-eight percent of existing models assessed antipsychotics; however, due to inconsistent conclusions reported by different studies, no antipsychotic can be considered clearly cost effective compared with the others. A very limited number of models suggest that the following non-pharmacological...Continue Reading

References

Nov 25, 2003·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Wendy J Ungar, Maria T Santos
Sep 14, 2004·Health Technology Assessment : HTA·Z PhilipsJ Glanville
Sep 15, 2005·Journal of Clinical Psychopharmacology·Roy H PerlisPhilip S Wang
Nov 2, 2005·Journal of Health Services Research & Policy·Nicola CooperAlexander Sutton
Aug 10, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Stephen M BeardEckart Rüther
Nov 8, 2006·Acta Psychiatrica Scandinavica. Supplementum·P Gutierrez-RecachaJ L Ayuso-Mateos
May 24, 2007·Journal of Evaluation in Clinical Practice·Mark Bounthavong, Mark P Okamoto
Nov 14, 2007·International Journal of Clinical Practice·M ObradovicM Kos
Dec 18, 2007·Current Medical Research and Opinion·B M S HeegB A Van Hout
May 21, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Bart HeegBen van Hout
Aug 2, 2008·Bulletin of the World Health Organization·Dan ChisholmShekhar Saxena
Apr 9, 2009·Cost Effectiveness and Resource Allocation : C/E·Nicolas M FuriakSteven D Culler
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Aug 12, 2009·Revista de saúde pública·Leandro Mendonça LindnerGeder Evandro Motta Grohs
Jul 10, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Li YangPeng Dong
Sep 2, 2010·Applied Health Economics and Health Policy·Marja HensenBen van Hout
May 17, 2011·Cost Effectiveness and Resource Allocation : C/E·Pudtan PhanthunaneMelanie Bertram
Jul 21, 2011·Nordic Journal of Psychiatry·Eva LindströmChristophe Sapin
Jul 4, 2012·Annals of General Psychiatry·Thomas R EinarsonMichiel E H Hemels
Jul 26, 2012·Health Economics Review·Antonio J García-RuizMiguel A Casado
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·J Jaime CaroUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Sep 29, 2012·Journal of Medical Economics·M TreurB Heeg
Dec 19, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Paul TappendenMatthew Stevenson
Mar 26, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Don HusereauElizabeth Loder
Jul 13, 2013·Journal of Medical Economics·Thomas R EinarsonMichiel E H Hemels
Aug 27, 2013·Applied Health Economics and Health Policy·Jan ZeidlerStephan Heres
Feb 26, 2014·Journal of Medical Economics·Jean LachaineMaud Beillat
Feb 26, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Birgitta von SchéeleAnita Patel
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Taehwan Park, Karen M Kuntz
Dec 9, 2014·Global Public Health·Nguyen Quynh AnhNguyen Thanh Huong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here